The ECtHR’s Reluctance to Review Cannabis Prohibition: A Breach of Its Own Standards?

[Roar Mikalsen is the Leader of the Alliance for Rights-Oriented Drug Policies (AROD)]

The author is the lead applicant in the Mikalsen v. Norway applications before the ECtHR (app. no. 67078/10 and subsequent filings). This connection is disclosed for full transparency

The European Court of Human Rights (ECtHR) serves as the ultimate arbiter of the European Convention on Human Rights (ECHR), ensuring that state actions align with fundamental rights. Articles 8 (right to respect for private and family life) and 13 (right to an effective remedy) empower the Court to assess whether national policies, such as cannabis prohibition, interfere with individual liberties in a manner that is lawful, pursues a legitimate aim, and is necessary in a democratic society. However, the ECtHR has shown a marked reluctance to engage substantively with drug policy challenges, often declaring such cases “manifestly ill-founded” under Article 35(3)(a). This pattern not only insulates prohibition from scrutiny but also perpetuates potential violations of human rights, including privacy, health, non-discrimination, and freedom from arbitrary detention. Drawing on specific ECtHR judgments, comparative national court practices, and UN/CoE reports, this article explores how prohibition may contravene these rights and argues for greater judicial engagement.

The Empirical and Human Rights Case Against Prohibition

Cannabis prohibition in Europe, rooted in the 1961 UN Single Convention on Narcotic Drugs, has prioritised criminalisation for over six decades in pursuit of a “drug-free society.” Yet empirical data continues to demonstrate the limited effectiveness of this approach. According to the European Union Drugs Agency, an estimated 24 million adults (aged 15–64) reported past-year cannabis use in the most recent available surveys, while illicit markets remain active despite sustained enforcement efforts. In 2023, more than 1.6 million drug law offences were recorded across the EU, the large majority of which related to cannabis. Drug offences continue to be the most common principal offence among sentenced prisoners, accounting for 16.7% of the sentenced prison population. Drug-induced deaths stood at nearly 7,500 in 2023, with prohibition’s contribution to black markets and the diversion of resources away from harm reduction measures widely recognised as aggravating factors.

The Council of Europe’s Parliamentary Assembly baseline study on human rights and drug policy (2020) emphasises that punitive approaches can lead to degrading treatment (Article 3), arbitrary detention (Article 5), and discrimination (Article 14), as they disproportionately affect vulnerable groups. CoE Resolution 2335 (2020) calls for integrating human rights into drug policies, recommending decriminalisation for personal use to mitigate these harms.

UN reports reinforce these concerns. The 2025 World Drug Report highlights how punitive drug policies contribute to mass incarceration, violence, and health crises, infringing upon the right to life and the right to health. The UN High Commissioner for Human Rights has described the “war on drugs” as a failure and has called for the regulation of illicit markets in order to better protect public health.

Germany, home to nearly one-fifth of the European Union’s population, introduced a regulated cannabis model in 2024. Combined with developments in Malta and other jurisdictions, a growing number of Europeans now live under more liberal cannabis regimes. This divergence between evolving national practices and the Court’s consistent refusal to examine the merits of prohibition cases raises questions about the Court’s willingness to engage with evolving standards in this area.

ECtHR Case Law: Deference and Procedural Barriers

The ECtHR’s drug policy jurisprudence exhibits significant deference to the national margin of appreciation. In Thörn v. Sweden (app. no. 24547/18, judgment of 1 September 2022), a paraplegic applicant who cultivated cannabis for his own medical use was convicted and fined approximately 500 euros. The Court found no violation of Article 8, granting Sweden a wide margin of appreciation. Notably, the applicant in that case accepted the general legitimacy of the prohibition and only sought a personal exemption on medical grounds. This may explain the Court’s limited scrutiny in that case.

The Mikalsen v. Norway applications offer a more direct test of the Court’s willingness to engage with the core issue. In these applications (starting with application no. 67078/10, lodged in 2010 and continuing through subsequent filings), the applicants have directly challenged the legitimate purpose of cannabis prohibition itself, citing evolving scientific evidence, alternative regulatory models, and the documented harms of criminalisation. Since 2010, applicants have repeatedly sought effective remedies under Article 13, yet the Court has consistently declared the cases manifestly ill-founded under Article 35(3)(a). Most recently, on 11 June 2026, a further application in this series was again declared inadmissible by a single judge, without any examination of the merits. This decision continues the same pattern of rejection that has now persisted for more than fifteen years.

This approach stands in marked contrast with the Court’s more rigorous scrutiny in cases such as SAS v. France (2014, app. no. 43835/11), where the Grand Chamber carefully examined the legitimate aim of the measure (“living together”) before upholding the face-veil ban under Article 8(2). The repeated procedural barrier raises questions about the appearance of justice — a principle famously articulated by the Court in Delcourt v. Belgium (1970) — and may undermine public confidence in the effective protection of Convention rights.

This contrast is striking. In areas such as freedom of expression, privacy in the digital sphere, and the rights of sexual minorities, the Court has often subjected state interference to relatively rigorous scrutiny. By contrast, in the field of drug policy, the Court has consistently granted states a very wide margin of appreciation and declined to examine whether criminal prohibition continues to pursue a legitimate aim. This disparity suggests that certain liberty interests — particularly those associated with personal autonomy in the context of drug use — receive significantly less protection under the Convention than other rights, even though such policies result in widespread criminalisation and imprisonment across Europe.

Granting states such a wide margin of appreciation in drug policy carries significant implications. Where policies have historically been influenced by moral and political sensitivities, extensive judicial deference risks insulating restrictions on personal autonomy from meaningful review, even as substantial evidence accumulates regarding their effectiveness and consequences.

Comparative Analysis of National Courts’ Practices

National courts reveal considerable divergence, underscoring the need for clearer Convention standards. Portugal’s 2001 decriminalisation, upheld by the Supreme Court, treats possession as an administrative offence and has reduced overdoses without increasing use. Germany’s Federal Constitutional Court ruled in 1994 that minor possession penalties are disproportionate in cases of occasional personal use, paving the way for the 2024 Cannabis Act. Spain’s Supreme Court permits private social clubs for non-profit distribution among members but prohibits public sales, creating a regulatory grey area. The Netherlands’ Supreme Court upholds coffee-shop tolerance while restricting access for foreigners in line with ECJ rulings (2010), balancing health and tourism concerns. Malta’s 2021 reform allows possession up to 7 g, home cultivation of 4 plants, and regulated non-profit cannabis clubs.

While Article 14 ECHR does not impose a general requirement of cross-jurisdictional harmonisation, such divergences illustrate inconsistent protection of the same Convention right across member states. By contrast, constitutional courts in other jurisdictions — such as the Mexican Supreme Court, the Colombian Constitutional Court, and the South African Constitutional Court (Minister of Justice v Prince, 2018) — have directly examined the legitimacy of cannabis prohibition on grounds of personal autonomy and privacy.

Broader Human Rights Violations and the EU Drugs Strategy

Prohibition may foster violations beyond arbitrary detention (ECHR Article 5) and discrimination (ECHR Article 14), including interferences with privacy and personal autonomy (ECHR Article 8). The drug laws’ demonstrable long-term effect has often been to serve as a mechanism of social control and the consolidation of political power, and the resulting risk of abuse of authority is becoming increasingly difficult to ignore. In a 1994 interview, Nixon’s domestic policy chief John Ehrlichman candidly acknowledged that the US-led war on drugs had little connection to public-health concerns and was instead designed to target specific communities and political opponents. While that historical example is US-specific, it illustrates a broader pattern in which prohibition has sometimes been deployed to limit other fundamental rights under the guise of protecting public morals — a practice that may engage ECHR Article 18, which prohibits the misuse of restrictions permitted under the Convention.

The persistent failure of the ECtHR to engage substantively with these issues places the Convention system under considerable strain. The rights of millions of Europeans are at stake, and as individual nations advance with evidence-based reforms, the Council of Europe must at some point assume its responsibility and provide principled guidance in this contested field, thereby ensuring the Convention remains a living instrument. Failure to do so risks eroding public confidence in the rule of law.

Photo by Rick Proctor on Unsplash